HANOI, VIETNAM – Media OutReach – 2 August 2021 – Supported by the Vietnamese Government and Health Ministry, Vingroup (HOSE: VIC) and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced a contract regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ mRNA COVID-19 vaccine candidate for sales and use in Vietnam.  With a planned capacity of up to 200 million doses per year, Vingroup is expected to produce its first batches of the COVID-19 vaccine in early 2022.  

Arcturus Therapeutics is a leading clinical stage company focused on messenger RNA (mRNA) medicines – one of the most advanced medicinal technologies in the world. Under the terms of the arrangement, VinBioCare – a member of Vingroup – will, with consultation from Arcturus, build out a manufacturing facility in Vietnam; and Arcturus will provide to VinBioCare access to proprietary technologies and processes for the final drug product manufacturing of Arcturus’ investigational COVID-19 vaccine. Arcturus will provide VinBioCare with an exclusive license to manufacture the vaccine at the Vietnam facility solely for sales and use in Vietnam.

VinBioCare’s vaccine factory is located inside VinSmart’s electronic equipment complex in Hoa Lac Hi-tech Park (Thach That District, Hanoi), with a total estimated investment of 200 million USD and capacity of 200 million doses per year.

Currently, VinBioCare has already signed equipment procurement contracts for this factory. As planned, all equipment will be transported to Vietnam via special flights to ensure timely arrivals in September 2021. So far, construction has also completed while the installation of equipment is expected to be finalized in November 2021.

To ensure the highest production standards, VinBioCare has cooperated with Rieckermann (Germany) – one of the leading machinery & industrial solution providers in the pharmaceuticals industry – to promptly carry out the construction of the 8,807m2 factory following GMP requirements.

“In response to the Vietnamese Government’s guideline on COVID-19 vaccine supply for Vietnam in the time of limited source of supply and outbreaks, Vingroup has proactively looked for prestigious international partners for cooperation and conducted procurement and construction of the vaccine factory as quickly as possible.” – said Vingroup’s Vice Chairwoman Le Thi Thu Thuy. “Vingroup really expects to make a modest contribution to the fight against COVID-19 in Vietnam and the world, so that all people can live a normal life again.”

Arcturus investigational COVID-19 vaccines utilizes Arcturus’ lipid-mediated delivery system called LUNAR® delivery system, and Arcturus’ self-amplifying mRNA technology, known as STARR™. This self-amplifying technology is designed to promote a prolonged immune response using a lower dose compared to conventional mRNA vaccines. mRNA vaccine technology enables rapid modification of the antigen that could help to accelerate the development of vaccines against SARS-CoV-2 variants.

Notably, the vaccine candidate, called VBC-COV19-154 domestically, can be made in a lyophilized powder form which is favorable for packaging, storage, transport, distribution and supply.

As planned, VinBioCare will coordinate with the Vietnamese Health Ministry’s Administration of Science Technology & Training to carry out Phase 3 clinical trials of VBC-COV19-154 vaccine on 20,000 people in August 2021.

In December 2021, VinBioCare plan to complete and submit procedures to the Health Ministry to ask for approval for VBC-COV19-154 vaccine for emergency use in Vietnam.

Once produced domestically, VBC-COV19-154 is expected to be cheaper than products of similar segment in the market. Notably, VinBioCare will provide COVID-19 vaccine at break-even price excluding investment costs in Vietnam during the time of pandemic.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

About Vingroup and VinBioCare

As the largest private conglomerate in Vietnam and one of the largest in Asia, Vingroup is currently doing business in three core sectors namely technology, industry and services. In all sectors it has participated in, Vingroup is always a pioneer that leads market trends and creates world-class products and services of Vietnam. Find out more at: https://www.vingroup.net/en

VinBioCare Biotechnology JSC (a member company of Vingroup) is a Vietnamese business working on vaccine and biological products. VinBioCare’s major resources are transferred from Viet A Corporation – a specialist in biotechnology with substantial market shares in Vietnam. The corporation was also Vietnam’s first producer of real-time PCR test kit for SARS-CoV-2 and is currently the supplier to about 90% of health care centers throughout the country.

#vingroup #VinBioCare #Arcturus

A Wide Spectrum of Medical Specialties under One Roof to Support Expansion and Meet Demand for One-stop Quality Medical Services

HONG KONG SAR – Media OutReach – 2 August 2021 –  Hong Kong Medical Consultants Holdings Limited (“Hong Kong Medical Consultants”, “HKMC” or the “Group”), a leading multi-specialty medical services group in Hong Kong, announced today the grand opening of the HKMC Integrated Medical Centre on the 9^th Floor of Central Building, Central, Hong Kong.

HKMC Integrated Medical Centre provides a wide range of 11 medical specialties.

Established in 2013, HKMC is a multi-disciplinary private medical services group, operating under a doctor-led management team and chaired by its founder Dr. Kenneth Tsang. The Group comprises specialist doctors and allied healthcare professionals with extensive clinical experience in their respective areas of expertise.

With a GFA of approximately 16,200 sq. ft. on the entire 9^th Floor of Central Building, the HKMC Integrated Medical Centre has been running smoothly since its commencement of operations in June 2021. The new Integrated Medical Centre is supported by a team of 15 specialist doctors spanning 11 medical specialties (Respiratory Medicine, Cardiology, Neurology, Geriatric Medicine, Nephrology, Paediatrics, Oncology, Psychiatry, Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolism and Rheumatology).

In October 2019, the Group also acquired Hong Kong Imaging and Diagnostic Centre Limited, which has two imaging and diagnoses centres and one laboratory located in Central, thereby providing the Group’s  diagnostic services with in-house imaging and other diagnostic facilities.

Dental services have been newly introduced in May 2021, expanding the Group’s capabilities in meeting the rising demand for private specialty services in Hong Kong, with an estimated CAGR of revenue of 5.8% increasing from HK$29.7 billion in 2020 to HK$37.3 billion in 2024[1].

HKMC will continue to recruit talented medical practitioners in Hong Kong by taking advantage of the trend of consolidation of smaller medical practices in Hong Kong.  A number of key intitaitves will be spearheaded to provide a wider variety of specialist medical services, including:

• the addition of dermatology specialist service by setting up a new dermatology centre. It will lead to our further growth because there is a strong demand for dermatology services for both medical and aesthetic purposes;
• the extension of oncology specialist services by setting up a new oncology centre;
• HKMC’s purchase of the 6^th floor of Euro Trade Centre in Central (GFA of approximately 5,200 sq. ft.) in March 2021, and the Group will establish a comprehensive diagnostic centre with CT, MRI, ultrasound and other related imaging and diagnostic facilities on the same floor;
• the recently introduced medical concierge services of HKMC will assist the promotion of new businesses through the initiation of health check programmes; and
• the licensed wholesale pharmacy where HKMC can store and distribute medicine to its Medical Centres as well as to other third-party private medical practitioners on a wholesale basis.

About Hong Kong Medical Consultants (HKMC)

Established in 2013, HKMC is a multi-specialty private medical services group in Hong Kong, comprising specialist doctors and allied healthcare professionals with extensive clinical experience in their respective areas. HKMC provides a wide range of specialist medical services, complemented by various allied health and medical management services under two brands (namely “Hong Kong Medical Consultants” and “Hong Kong Imaging and Diagnostic Centre”). Currently, the Group covers 11 medical specialties, including Respiratory Medicine, Cardiology, Neurology, Geriatric Medicine, Nephrology, Paediatrics, Oncology, Psychiatry, Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolism and Rheumatology.

Website: www.hkmedicalconsultants.com

#HongKongMedicalConsultants #HKMC

HONG KONG SAR & SHANGHAI, CHINA – Media OutReach – 2 August 2021 – Hang Lung Properties has been awarded the “2021 Corporate Social Responsibility Model Award” at the 10^th China Finance Summit, recognizing its long-term commitment to corporate social responsibility and promoting community investment and sustainable development for the community – a tangible expression of the company’s motto, We Do It Well.  

Hang Lung Properties has been awarded the “2021 Corporate Social Responsibility Model Award” at the 10th China Finance Summit, recognizing its long-term commitment to corporate social responsibility and promoting community investment – a tangible expression of the company’s motto, We Do It Well. 

Mr. Weber Lo, Chief Executive Officer of Hang Lung Properties, said, “As a leading real estate developer, Hang Lung pursues sustainable growth by connecting our customers and communities. Our 2030 sustainability goals and targets are an operational priority, helping us on our path become one of the most sustainable real estate companies in the world. An integral part of our corporate culture is the distilling of our concern for “caring about people” through all levels of the organization. In all our endeavors, from talent cultivation and employee wellbeing to environmental protection and community engagement, we are committed to creating shared value for all our stakeholders. To this end, we encourage our employees to be actively involved in volunteer activities, and continuously commit our resources to sustainable community investment initiatives.”

Hang Lung has always been committed to fulfilling its corporate social responsibilities and established the “Hang Lung As One Volunteer Team” in Hong Kong in 2012 to take the lead in community projects. In addition to Hong Kong, currently all 11 projects across the company’s Mainland portfolio encompassing Shanghai, Shenyang, Jinan, Wuxi, Tianjin, Dalian, Kunming, Wuhan, and Hangzhou, have formed teams of local volunteers with a focus on youth development and education, elderly services, and environment protection. Leveraging its corporate resources and the generous commitment of its staff, the company hopes to build an inclusive and diverse society. In the past year alone, Hang Lung As One received the support of close to 1,700 members, who participated in over 100 service programs, reaching over 20,000 beneficiaries and contributing over 13,000 service hours. To commemorate the company’s anniversary in a meaningful way, our volunteer teams consisting of staff and their family members, friends, and tenants, will join forces in a nation-wide volunteer activity every September.

Volunteerism is part of the Hang Lung corporate culture. By providing opportunities to serve, training, and due recognition, the company encourages staff, along with their family members and friends, to join volunteer programs to address social needs. The “2021 Corporate Social Responsibility Model Award” and the “2020 Public Welfare Practice Award” previously awarded at the 10^th China Charity Festival are an encouraging recognition of the company’s commitment and its people’s dedication to community investment.

The “2021 Corporate Social Responsibility Model Award” was presented by the China Finance Summit. Established in 2012, the China Finance Summit is one of the most influential events in China’s economic field and celebrates its 10^th edition this year. It covers a range of programs including talks, executive conversation, and a sharing section with more than 1,000 representatives from the business, politics, academia, and media sectors to explore the driving forces of China’s economic development.

About Hang Lung Properties

Hang Lung Properties Limited (stock code: 00101) creates compelling spaces that enrich lives. Headquartered in Hong Kong, Hang Lung Properties develops and manages a diversified portfolio of world-class properties in Hong Kong and the nine Mainland cities of Shanghai, Shenyang, Jinan, Wuxi, Tianjin, Dalian, Kunming, Wuhan and Hangzhou. With its luxury positioning under the “66” brand, the company’s Mainland portfolio has established its leading position as the “Pulse of the City”. Hang Lung Properties is recognized for leading the way in enhanced sustainability initiatives in real estate as it pursues sustainable growth by connecting customers and communities.

At Hang Lung Properties – We Do It Well.

For more information, please visit www.hanglung.com.

#HangLungProperties

SINGAPORE – Media OutReach – 2 August 2021 – 7-Eleven’s crowd-favourite Durian Snowskin Mooncakes are BACK after a complete sell-out last year! Start your Mid-Autumn or Mooncake festival preparations early – simply pre-order these 7-Eleven Durian Snowskin Mooncakes at participating 7-Eleven stores island wide, available now until 18 September 2021. Encased in a premium box and a matching cooler bag to keep your mooncakes fresh, these will make the perfect gift for your family and friends!

100% Pure Durian Indulgence

These exquisite mooncakes are encased in soft, smooth snowskin and boast a 100% durian filling without added sugar, preservatives, or cream. Enjoy pure durian deliciousness in each bite!

Fans of the “king of fruits” are in for a decadent treat! 7-Eleven Durian Snowskin Mooncakes are available in two crowd-pleasing varieties:

Mao Shan Wang Mooncakes (4pcs, U.P. $70) – these mooncakes are filled with what is arguably the most popular durian variety, famous for its rich and creamy texture and signature bittersweet taste.

D24 Mooncakes (4pcs, U.P. $65) – Just as moreish yet with a slightly milder aftertaste, perfect for those who prefer a more subtle aroma.

Can’t decide? Get the best of both worlds with our Assorted Flavours Mooncakes (4 pcs, U.P. $70) consisting two of each flavour.

You can also be sure of the quality and freshness of these mooncakes. Each mooncake undergoes High Pressure Processing, a cold pasteurisation technique and freezing process that preserves the durian’s fragrant and creamy taste and texture. These mooncakes are also halal-certified.

Enjoy $10 off along with your mooncakes pre-order!

Ordering your mooncakes could not be easier. Simply pre-order them from 2 August to 18 September 2021 with collection available at these selected 48 participating stores.  What’s more, enjoy $10 off our Assorted Flavours Mooncakes (4pcs) with purchase of Mao Shan Wang Mooncakes (4pcs) or D24 Mooncakes (4pcs)!

For more detail on the promotion and pricing, please refer to this summary table:

Further promotions and updates can be found on the 7-Eleven Singapore Facebook page so stay tuned!

About 7-Eleven

Established in Singapore in 1983, 7-Eleven has since expanded to more than 400 stores island-wide to become the leading 24-hour convenience chain store. We take pride in serving the Singapore community 24 hours a day, 365 days a year. 7-Eleven emphasises convenience and value by offering a wide array of quality products, food and services to satisfy the needs of its customers. Think 7-Eleven and what comes to mind are the refreshing Slurpee, 7CAFÉ as well as a wide range of quality ready meals and sandwiches under 7-SELECT. 7-Eleven is also a 24/7 one-stop destination for customers who need to access bill payment services in their own time. Our services cover payment of utilities, courier services, and cash withdrawal.

For more information, visit www.7-eleven.com.sg

#7ElevenSingapore